 |
Top 10 Urology startups in USA
Oct 10, 2024 | By Jason Kwon | 16 |
1
Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
2
Funding: $237.5M
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
3
Funding: $210M
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
4
Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
5
Funding: $97.2M
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
6
Funding: $51M
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
7
Funding: $26.9M
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
SonoMotion is developing non-invasive ultrasonic solutions for kidney stone disease. It allows to avoid surgical procedures by using long pulses of sound waves to push the smaller stones from the kidney safely and without anesthesia.
9
Funding: $9.1M
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
Butterfly has designed an anatomically shaped nitinol implant, which is positioned in the prostatic urethra in order to open the space and relieve BPH symptoms. The device comes in multiple sizes, and, unlike more invasive approaches, does not require any resection, cutting, or burning of prostatic tissue. The procedure can be completed in under six minutes in the urologist’s office.
10
Funding: $3.8M
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
Oxalo Therapeutics develops a first-of-its-kind peptide-based drug to prevent kidney stones.
